Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Blood-based biomarkers present a considerable challenge: technically, as blood is a complex tissue and conceptually, as blood lacks direct contact with brain. Nonetheless, increasing evidence suggests that there is a blood protein signature, and possibly a transcript signature, that might act to increase confidence in diagnosis, be used to predict progression in either disease or prodromal states, and that may also be used to monitor disease progression. Evidence for this optimism comes partly from candidate protein studies, including those suggesting that amyloid-beta measures might have value in prediction and those studies of inflammatory markers that consistently show change in Alzheimer's disease, and partly from true proteomics studies that are beginning to identify markers in blood that replicate across studies and populations.

Original publication

DOI

10.2217/bmm.09.84

Type

Journal article

Journal

Biomark Med

Publication Date

02/2010

Volume

4

Pages

65 - 79

Keywords

Alzheimer Disease, Amyloid beta-Peptides, Apolipoproteins E, Biomarkers, C-Reactive Protein, Genetic Markers, Homocysteine, Humans, Longitudinal Studies, Proteomics, RNA